Filed by Oaktree Acquisition Corp. II (Commission File
No. 001-39526)
Pursuant to Rule 425 under the Securities Act of 1933
And Deemed Filed und Rule 14a-12 under the Securities Exchange Act of 1934
Subject Company: Alvotech Holdings S.A.
AVT02, Alvotechs Biosimilar to High Concentration
Formulation of Adalimumab (Humira®)
Approved for Use in European Union
REYKJAVIK,
ICELAND (DECEMBER 15, 2021) Alvotech Holdings S.A. (Alvotech), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, received approval for
AVT02 (100 mg/mL), the companys high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15. The centralized marketing authorization in the
European Union (EU) follows the recommendation of the Committee for Medicinal Products for Human Uses (CHMP) for approval of AVT02 in September, and includes all EU Member States, as well as countries in the European Economic Area (EEA),
Iceland, Liechtenstein and Norway.
AVT02 is a high concentration biosimilar to adalimumab
(Humira®), which is used to treat a range of certain inflammatory conditions. Adalimumab inhibits tumor necrosis factor, which is a protein in the body that can cause inflammation. Humira® (adalimumab) recorded global sales of about US$20 billion in 2020, making it the highest grossing medicine in the world.
We are thrilled by the ECs approval of our high concentration biosimilar to
Humira®, said Róbert Wessman, Founder and Chairman of Alvotech. As a company, we develop our products with global markets in mind, and we are delighted to receive our first
regulatory approval for AVT02.
Mark Levick, CEO of Alvotech, added, Alvotech is dedicated to making patients lives better by improving
access to affordable biosimilar medicines. This news is another milestone in that journey.
On Dec. 7, 2021, Alvotech and Oaktree Acquisition Corp.
II (NYSE: OACB.U, OACB, OACB WS), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (Oaktree), announced they had entered into a definitive business combination agreement. Upon completion
of the transaction, the combined companys securities are expected to be traded on NASDAQ under the symbol ALVO.
About Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech
seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotechs
current pipeline contains seven biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.
For more
information, please visit www.alvotech.com.